Intuitive Surgical upgraded to Buy from Neutral at Goldman Goldman upgraded Intuitive Surgical and believes general surgery uptake will be the next leg of growth as surgical robotics evolves. The firm said the new da Vinci, upgrades, and add-ons will accelerate growth and that there is potential for management to return excess cash to shareholders. Price target raised to $715 from $591.
Intuitive Surgical appears fully valued at current levels, says Canaccord Canaccord said they would not add to positions of Intuitive Surgical at current levels as shares appear fully valued, if not slightly overvalued, relative to discounted cash flow. The firm also cited the company's operating headwinds and negative operating leverage. Canaccord reiterated its Hold rating but raised its price target to $517 from $487 on Intuitive Surgical shares.